News

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...
We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...
Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...
Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...
The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial ...
Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...
Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the ...
Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...